These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 35168096)

  • 1. S1P receptor modulators in Multiple Sclerosis: Detecting a potential skin cancer safety signal.
    Stamatellos VP; Rigas A; Stamoula E; Lallas A; Papadopoulou A; Papazisis G
    Mult Scler Relat Disord; 2022 Mar; 59():103681. PubMed ID: 35168096
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Disease-modifying agents for multiple sclerosis and the risk for reporting cancer: A disproportionality analysis using the US Food and Drug Administration Adverse Event Reporting System database.
    Stamatellos VP; Siafis S; Papazisis G
    Br J Clin Pharmacol; 2021 Dec; 87(12):4769-4779. PubMed ID: 33998034
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Switching disease-modifying therapies from sphingosine-1-phosphate receptor modulators to natalizumab or dimethyl fumarate restores immune responses after SARS-CoV-2 mRNA vaccination in patients with multiple sclerosis.
    Kanakura M; Kihara K; Kinoshita M; Sugimoto T; Murata H; Beppu S; Shiraishi N; Sugiyama Y; Koda T; Takahashi MP; Chinen I; Okuno T; Mochizuki H
    Clin Neurol Neurosurg; 2024 Aug; 243():108378. PubMed ID: 38901377
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Translated article] Risk of Skin Cancer Associated with Disease-Modifying Therapies in Multiple Sclerosis: A Comprehensive Evidence Review.
    Brufau-Cochs M; Mansilla-Polo M; Morgado-Carrasco D
    Actas Dermosifiliogr; 2024 Sep; 115(8):T781-T790. PubMed ID: 38972584
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Molecular and neuroimmune pharmacology of S1P receptor modulators and other disease-modifying therapies for multiple sclerosis.
    Kihara Y; Chun J
    Pharmacol Ther; 2023 Jun; 246():108432. PubMed ID: 37149155
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Potential adverse events associated with sphingosine-1-phosphate (S1P) receptor modulators in patients with multiple sclerosis: an analysis of the FDA adverse event reporting system (FAERS) database.
    Yang X; Yan Y; Liu S; Wang Z; Feng X
    Front Pharmacol; 2024; 15():1376494. PubMed ID: 38846098
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety and Monitoring of the Treatment with Disease-Modifying Therapies (DMTs) for Multiple Sclerosis (MS).
    Stamatellos VP; Papazisis G
    Curr Rev Clin Exp Pharmacol; 2023; 18(1):39-50. PubMed ID: 35418296
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Abuse and dependence potential of sphingosine-1-phosphate (S1P) receptor modulators used in the treatment of multiple sclerosis: a review of literature and public data.
    Schoedel KA; Kolly C; Gardin A; Neelakantham S; Shakeri-Nejad K
    Psychopharmacology (Berl); 2022 Jan; 239(1):1-13. PubMed ID: 34773483
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An update on the use of sphingosine 1-phosphate receptor modulators for the treatment of relapsing multiple sclerosis.
    Dumitrescu L; Papathanasiou A; Coclitu C; Garjani A; Evangelou N; Constantinescu CS; Popescu BO; Tanasescu R
    Expert Opin Pharmacother; 2023 Mar; 24(4):495-509. PubMed ID: 36946625
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Association Between Disease-Modifying Therapies Prescribed to Persons with Multiple Sclerosis and Cancer: a WHO Pharmacovigilance Database Analysis.
    Dolladille C; Chrétien B; Peyro-Saint-Paul L; Alexandre J; Dejardin O; Fedrizzi S; Defer G
    Neurotherapeutics; 2021 Jul; 18(3):1657-1664. PubMed ID: 34231126
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sphingosine 1-phosphate receptor modulators in multiple sclerosis treatment: A practical review.
    Coyle PK; Freedman MS; Cohen BA; Cree BAC; Markowitz CE
    Ann Clin Transl Neurol; 2024 Apr; 11(4):842-855. PubMed ID: 38366285
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bioavailable central nervous system disease-modifying therapies for multiple sclerosis.
    Hartung HP; Cree BAC; Barnett M; Meuth SG; Bar-Or A; Steinman L
    Front Immunol; 2023; 14():1290666. PubMed ID: 38162670
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Oral Therapies for Multiple Sclerosis.
    Faissner S; Gold R
    Cold Spring Harb Perspect Med; 2019 Jan; 9(1):. PubMed ID: 29500302
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sphingosine 1-phosphate receptor modulators in multiple sclerosis and other conditions.
    McGinley MP; Cohen JA
    Lancet; 2021 Sep; 398(10306):1184-1194. PubMed ID: 34175020
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment with disease-modifying drugs for people with a first clinical attack suggestive of multiple sclerosis.
    Filippini G; Del Giovane C; Clerico M; Beiki O; Mattoscio M; Piazza F; Fredrikson S; Tramacere I; Scalfari A; Salanti G
    Cochrane Database Syst Rev; 2017 Apr; 4(4):CD012200. PubMed ID: 28440858
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Alopecia in Multiple Sclerosis Patients Treated with Disease Modifying Therapies.
    Porwal MH; Salter A; Patel D; Obeidat AZ
    J Cent Nerv Syst Dis; 2022; 14():11795735221109674. PubMed ID: 35769950
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sphingosine 1-Phosphate Receptor Modulators for Multiple Sclerosis.
    Roy R; Alotaibi AA; Freedman MS
    CNS Drugs; 2021 Apr; 35(4):385-402. PubMed ID: 33797705
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Siponimod to treat secondary progressive multiple sclerosis.
    Gajofatto A; Turatti M
    Drugs Today (Barc); 2020 Jan; 56(1):37-46. PubMed ID: 32055804
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A comprehensive review of varicella-zoster virus, herpes simplex virus and cryptococcal infections associated with sphingosine-1-phosphate receptor modulators in multiple sclerosis patients.
    Sharma K; Chaudhary D; Beard K; Srivastava S; Khalid SH; Sriwastava S
    Mult Scler Relat Disord; 2022 Mar; 59():103675. PubMed ID: 35168095
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Disproportional increase in psoriasis reports in association with B cell depleting therapies in patients with multiple sclerosis.
    Porwal MH; Patel D; Maynard M; Obeidat AZ
    Mult Scler Relat Disord; 2022 Jul; 63():103832. PubMed ID: 35512502
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.